Clover Health CLOV
$3.73 −$0.04 (-1.06%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.75 +0.57%
Open$3.75
Prev close$3.77
Day range$3.68 – $3.96
Volume7.25M
Market cap$2.00B
P/E (TTM)373.0
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$759.30M+52.9% YoY
Operating profit$6.44M+126.4% YoY
Net profit$6.44M+126.4% YoY
Diluted EPS$0.01+120.0% YoY
Free cash flow$69.48M+508.9% YoY
Operating cash flow$70.38M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin18.9%
Operating margin0.5%
Net margin0.5%
Return on equity3.4%
Return on assets1.9%
Return on invested capital3.4%
Current ratio1.55
Liabilities / assets48.1%
Cash & investments$332.74M
Net cash (debt)$332.74M
Free cash flow / sales4.8%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $759.30M | $743.17M | $749.19M | $1.92B | $487.71M |
| Total Operating Revenue | $759.30M | $743.17M | $749.19M | $1.92B | $487.71M |
| Cost of Revenue | $629.46M | $590.17M | $589.65M | $1.57B | $413.50M |
| Gross Profit | $129.85M | $153.00M | $159.54M | $355.90M | $74.21M |
| Operating Expense | $123.41M | $125.00M | $132.21M | $441.43M | $123.53M |
| Selling and Admin Expenses | $122.80M | $124.44M | $131.69M | $439.75M | $123.11M |
| -General & Admin Expense | $122.80M | $124.44M | $131.69M | $439.75M | $123.11M |
| Depreciation & Amortization & Depletion | $610,000.00 | $564,000.00 | $515,000.00 | $1.69M | $420,000.00 |
| -Depreciation & Amortization | $610,000.00 | $564,000.00 | $515,000.00 | $1.69M | $420,000.00 |
| Operating Profit | $6.44M | $28.00M | $27.33M | -$85.53M | -$49.32M |
| Pretax Profit | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Net Profit | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Profit from Continuing Operations | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Net Income to Parent Company | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Net Income to Common Stockholders | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Basic EPS | $0.01 | $0.05 | $0.05 | -$0.17 | -$0.10 |
| Diluted EPS | $0.01 | $0.05 | $0.05 | -$0.17 | -$0.10 |
| Net Non-Operating Interest Income (Expense) | – | – | – | $0.00 | – |
| Non-Operating Interest Expense | – | – | – | $0.00 | – |
| Other Income (Expense) | – | – | – | -$20,000.00 | -$1,000.00 |
| Gain on Sale of Security | – | – | – | -$20,000.00 | -$1,000.00 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | $0.00 |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | – |
| Net Income from Discontinuous Operations | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $753.68M | $720.33M | $697.73M | $541.01M | $541.01M |
| Total Current Assets | $535.06M | $485.45M | $448.02M | $307.86M | $307.86M |
| Cash and Cash Equivalents & Short-Term Investments | $332.74M | $243.10M | $203.54M | $120.26M | $120.26M |
| -Cash and Cash Equivalents | $268.07M | $198.84M | $173.27M | $78.30M | $78.30M |
| -Short Term Investments | $64.67M | $44.26M | $30.28M | $41.96M | $41.96M |
| Receivables | $169.55M | $202.74M | $202.69M | $158.74M | $158.74M |
| -Other Receivables | $169.55M | $202.74M | $202.69M | $158.74M | $158.74M |
| Prepaid Assets | $16.94M | $19.21M | $18.42M | $18.21M | $18.21M |
| Other Current Assets | $15.84M | $20.40M | $23.37M | $10.65M | $10.65M |
| Total Non-Current Assets | $218.62M | $234.88M | $249.71M | $233.16M | $233.16M |
| Net PPE | $7.75M | $7.23M | $6.90M | $6.39M | $6.39M |
| -Gross PPE | $7.75M | $7.23M | $6.90M | $13.99M | $13.99M |
| Investments and Advances | $179.86M | $199.91M | $214.68M | $199.66M | $199.66M |
| -Available for Sale Securities | $167.25M | $189.44M | $202.24M | $187.09M | $187.09M |
| -Held to Maturity Securities | $12.61M | $10.47M | $12.44M | $12.57M | $12.57M |
| Goodwill and Other Intangible Assets | $2.99M | $2.99M | $2.99M | $2.99M | $2.99M |
| Other Non-Current Assets | $28.02M | $24.75M | $25.13M | $24.12M | $24.12M |
| Total Liabilities | $362.81M | $344.07M | $358.30M | $232.31M | $232.31M |
| Total Current Liabilities | $345.90M | $323.33M | $336.58M | $208.82M | $208.82M |
| Payables | $302.92M | $286.30M | $299.59M | $189.46M | $189.46M |
| -Accounts Payable | $33.81M | $35.41M | $39.17M | $36.21M | $36.21M |
| -Other Payable | $269.10M | $250.89M | $260.42M | $153.25M | $153.25M |
| Current Accrued Expenses | $36.79M | $31.16M | $31.23M | $16.04M | $16.04M |
| Other Current Liabilities | $6.19M | $5.88M | $5.77M | $3.32M | $3.32M |
| Total Non-Current Liabilities | $16.91M | $20.74M | $21.72M | $23.48M | $23.48M |
| Other Non-Current Liabilities | $16.91M | $20.74M | $21.72M | $23.48M | $23.48M |
| Total Equity | $390.87M | $376.26M | $339.43M | $308.70M | $308.70M |
| Stockholders' Equity | $390.87M | $376.26M | $339.43M | $308.70M | $308.70M |
| Capital Stock | $52,000.00 | $52,000.00 | $52,000.00 | $52,000.00 | $52,000.00 |
| -Common Stock | $52,000.00 | $52,000.00 | $52,000.00 | $52,000.00 | $52,000.00 |
| Additional Paid-In Capital | $2.72B | $2.71B | $2.70B | $2.68B | $2.68B |
| Retained Earnings | -$2.23B | -$2.23B | -$2.26B | -$2.29B | -$2.29B |
| Less: Treasury Stock | -$95.87M | -$95.87M | -$94.08M | -$86.19M | -$86.19M |
| Gains/Losses Not Affecting Retained Earnings | -$3.35M | -$1.55M | -$672,000.00 | $528,000.00 | $528,000.00 |
| -Accumulated Depreciation | – | – | – | -$7.60M | -$7.60M |
| -Other Intangible Assets | – | – | – | $2.99M | $2.99M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $70.38M | $25.19M | $107.90M | -$66.93M | -$68.15M |
| Net cash flow from continuing operations | $70.38M | $25.19M | $107.90M | -$66.93M | -$68.15M |
| Net Income from Continuing Operations | $6.44M | $28.00M | $27.33M | -$85.55M | -$49.32M |
| Gain/Loss from Continuing Operations | $1,000.00 | -$2,000.00 | -$28,000.00 | -$959,000.00 | -$353,000.00 |
| Depreciation & Depletion & Amortization | $610,000.00 | $564,000.00 | $515,000.00 | $1.69M | $420,000.00 |
| Other Non-Cash Items | -$175,000.00 | -$747,000.00 | -$300,000.00 | -$1.57M | -$956,000.00 |
| Change in Working Capital | $55.49M | -$11.71M | $68.10M | -$84.20M | -$42.86M |
| -Change in Receivables | $33.18M | -$46,000.00 | -$43.95M | -$65.95M | -$55.23M |
| -Change in Prepaid Assets | $2.28M | -$790,000.00 | -$214,000.00 | -$5.04M | -$5.74M |
| -Change in Payables and Accrued Expense | $4.04M | -$3.84M | $18.15M | -$1.41M | $2.14M |
| -Change in Other Current Assets | $1.29M | $3.36M | -$13.73M | -$5.92M | $4.53M |
| -Change in Other Current Liabilities | -$3.52M | -$869,000.00 | $677,000.00 | -$2.74M | -$1.35M |
| -Change In Other Working Capital | $18.21M | -$9.53M | $107.17M | -$3.15M | $12.79M |
| Net cash flow from investing | -$2.88M | -$32,000.00 | -$5.07M | $4.08M | -$35.00M |
| Net Cash Flow from Continuing Investing Activities | -$2.88M | -$32,000.00 | -$5.07M | $4.08M | -$35.00M |
| Net PPE Purchase and Sale | -$898,000.00 | -$682,000.00 | -$854,000.00 | -$2.04M | -$597,000.00 |
| Net Investment Purchase and Sale | -$1.98M | $650,000.00 | -$4.21M | $6.12M | -$34.40M |
| Financing Cash Flow | $1.73M | $416,000.00 | -$7.86M | -$53.38M | -$8.61M |
| Net Cash Flow from Continuing Financing Activities | $1.73M | $416,000.00 | -$7.86M | -$53.38M | -$8.61M |
| Net Common Stock Issuance | $1.73M | $416,000.00 | -$7.86M | -$53.38M | -$8.61M |
| Ending Cash Balance | $268.07M | $198.84M | $173.27M | $78.30M | $78.30M |
| Net Change in Cash | $69.23M | $25.57M | $94.96M | -$116.24M | -$111.75M |
| Beginning Cash Balance | $198.84M | $173.27M | $78.30M | $194.54M | $190.06M |
| Free Cash Flow | $69.48M | $24.51M | $107.04M | -$68.98M | -$68.75M |
| Cash Flow from Discontinued Operating Activities | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on CLOV.
Sign in to join the discussion.